Evaluation of the EMPAR study population on the basis of metabolic phenotypes of selected pharmacogenes [0.03%]
基于选定药理基因的代谢表型对EMPAR研究人群的评估
Jochen Fracowiak,Tatjana Huebner,Steffen Heß et al.
Jochen Fracowiak et al.
The impact of genetic variability of pharmacogenes as a possible risk factor for adverse drug reactions is elucidated in the EMPAR (Einfluss metabolischer Profile auf die Arzneimitteltherapiesicherheit in der Routineversorgung/English: infl...
Impact of CYP2C19 metaboliser status on SSRI response: a retrospective study of 9500 participants of the Australian Genetics of Depression Study [0.03%]
一种基于澳大利亚抑郁症遗传研究的9500名受试者的回顾性分析：CYP2C19代谢状态对SSRIs疗效的影响
Adrian I Campos,Enda M Byrne,Brittany L Mitchell et al.
Adrian I Campos et al.
Background: Variation within the CYP2C19 gene has been linked to differential metabolism of selective serotonin reuptake inhibitors (SSRIs). Pharmacogenetic recommendations based on the effect of CYP2C19 variants have bee...
A single nucleotide polymorphism-based formula to predict the risk of propofol TCI concentration being over 4 µg mL-1 at the time of loss of consciousness [0.03%]
一种基于单核苷酸多态性的预测丙泊酚靶控浓度达到失意识时超过4μg/mL风险的公式
Zhuoling Zheng,Faling Xue,Haini Wang et al.
Zhuoling Zheng et al.
We aim to develop a formula based on single nucleotide polymorphisms (SNPs) to predict whether the propofol target-controlled infusion (TCI) concentration would be over 4 μg mL-1 at the time of loss of consciousness (LOC). We recruited 184...
Association of ITPA gene polymorphisms with adverse effects of AZA/6-MP administration: a systematic review and meta-analysis [0.03%]
ITPA基因多态性与AZA/6-MP不良反应关联的系统评价和Meta分析
Evaggelia Barba,Panagiota I Kontou,Ioannis Michalopoulos et al.
Evaggelia Barba et al.
Azathioprine (AZA) and its metabolite, mercaptopurine (6-MP), are widely used immunosuppressant drugs. Polymorphisms in genes implicated in AZA/6-MP metabolism, reportedly, could account in part for their potential toxicity. In the present ...
Correction to: PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors [0.03%]
PIK3R5基因预测器预测血管生成途径抑制剂诱导的高血压校正版
Julia C F Quintanilha,Alessandro Racioppi,Jin Wang et al.
Julia C F Quintanilha et al.
Published Erratum
The pharmacogenomics journal. 2022 Mar;22(2):145. DOI:10.1038/s41397-021-00264-2 2022
Arvind Jaya Shankar,Sudhir Jadhao,Wendy Hoy et al.
Arvind Jaya Shankar et al.
Indigenous Australians face a disproportionately severe burden of chronic disease relative to other Australians, with elevated rates of morbidity and mortality. While genomics technologies are slowly gaining momentum in personalised treatme...
PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors [0.03%]
VEGF通路抑制剂诱导的高血压的PIK3R5遗传预测因子
Julia C F Quintanilha,Alessandro Racioppi,Jin Wang et al.
Julia C F Quintanilha et al.
No biomarkers are available to predict patients at risk of developing hypertension induced by VEGF-pathway inhibitors. This study aimed to identify predictive biomarkers of hypertension induced by these drugs using a discovery-replication a...
Application of long-read sequencing to elucidate complex pharmacogenomic regions: a proof of principle [0.03%]
长读长测序在复杂药理基因组区域解析中的应用：原理证明
Maaike van der Lee,William J Rowell,Roberta Menafra et al.
Maaike van der Lee et al.
The use of pharmacogenomics in clinical practice is becoming standard of care. However, due to the complex genetic makeup of pharmacogenes, not all genetic variation is currently accounted for. Here, we show the utility of long-read sequenc...
Association study of candidate DNA-repair gene variants and acute graft versus host disease in pediatric patients receiving allogeneic hematopoietic stem-cell transplantation [0.03%]
候选DNA修复基因变异与儿童患者接受同种异体造血干细胞移植后急性移植物抗宿主病的关联研究
C R S Uppugunduri,P Huezo-Diaz Curtis,T Nava et al.
C R S Uppugunduri et al.
Acute Graft versus Host Disease (aGvHD) grades 2-4 occurs in 15-60% of pediatric patients undergoing allogeneic haematopoietic stem-cell transplantation (allo-HSCT). The collateral damage to normal tissue by conditioning regimens administer...
Nine-gene pharmacogenomics profile service: The Mayo Clinic experience [0.03%]
九基因药物基因组学谱型服务：梅奥诊所的经验
Eric T Matey,Ashley Kate Ragan,Lance J Oyen et al.
Eric T Matey et al.
Purpose: The Pharmacogenomics (PGx) Profile Service was a proof-of-concept project to implement PGx in patient care at Mayo Clinic. Methods: ...